
| 2008 | |
|---|---|
| Criterium: | Position: |
| Overall Score: | > 1000 |
| Total Project Funding: | > 1000 |
| Total Project Funding per Partner: | > 1000 |
| Total Number of Projects: | > 1000 |
| Networking Rank (Reputation): | > 1000 |
| Partner Constancy: | 900-1000 |
| Project Leadership Index: | 900-1000 |
| Diversity Index: | > 1000 |
| 2007 | |
| Criterium: | Position: |
| Overall Score: | > 1000 |
| Total Project Funding: | > 1000 |
| Total Project Funding per Partner: | > 1000 |
| Total Number of Projects: | > 1000 |
| Partner Constancy: | 800-900 |
| Project Leadership Index: | 800-900 |
| Diversity Index: | > 1000 |
Total funding allocated to projects this organisation participated or coordinated
Total funding / No of participants
Total number of projects: 4
As coordinator: 0
As participant: 4
Sole participant: 0
Coordinator / Participant Ratio: 0*
*Ratio includes only projects with > 2 partners
| Total project funding [€]: | Projects [No]: | |||||
|---|---|---|---|---|---|---|
| Year: | coordinator* | participant* | per partner | as coordinator | as participant | |
| 2000 | 0 | 2.738.150 | 342.269 | 1 | ||
| 2004 | 0 | 9.100.000 | 275.758 | 1 | ||
| 2006 | 0 | 9.876.546 | 379.867 | 1 | ||
| 2008 | 0 | 12 | 0 | 1 | ||
Total number of partners:95
Partner loyalty:
Frequent Partner: (> 2 projects): 3
Rare Partner: 92
Frequent / Rare Partner Ratio: 0.03
| Category: | No: |
|---|---|
| BIOLOGICAL SCIENCES | 4 |
| RTD HORIZONTAL TOPICS | 1 |
| SOCIAL AND ECONOMIC CONCERNS | 1 |
| Start date | Project | acronym | role | funding | partners |
|---|---|---|---|---|---|
| 2008-04-01 | Embryonic stem cell-based novel alternative testing strategies | ESNATS | participant | 12 | 32 |
| 2006-11-01 | Engineering of the porcine genome for xenotransplantation studies in primates: a step towards clinical application | XENOME | participant | 9.876.546 | 26 |
| 2004-07-01 | Development of a novel approach in hazard and risk assessment or reproductive toxicity by a combination and application of in vitro, tissue and sensor technologies | REPROTECT | participant | 9.100.000 | 33 |
| 2000-02-01 | In vitro production of high quality mammalian oocytes for biotechnology, assisted reproduction, breeding and toxicology-teratology purposes | EX OVO OMNIA | participant | 2.738.150 | 8 |